TY - JOUR
T1 - An Overview of High-Efficacy Drugs for Multiple Sclerosis
T2 - Gulf Region Expert Opinion
AU - Alroughani, Raed
AU - Inshasi, Jihad Said
AU - Deleu, Dirk
AU - Al-Hashel, Jasem
AU - Shakra, Mustafa
AU - Elalamy, Osama Robin
AU - Shatila, Ahmed Osman
AU - Al-Asmi, Abdullah
AU - Al Sharoqi, Isa
AU - Canibano, Beatriz Garcia
AU - Boshra, Amir
N1 - Publisher Copyright:
© 2019, The Author(s).
PY - 2019/6/1
Y1 - 2019/6/1
N2 - This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration. Funding: Merck Serono Middle East FZ LTD.
AB - This article discusses the opinions of the multiple sclerosis (MS) experts in the Gulf region on the use of high-efficacy disease-modifying drugs (DMDs; natalizumab, fingolimod, alemtuzumab, cladribine tablets, and ocrelizumab) in clinical practice. The experts reviewed the current literature including pivotal clinical trials and meta-analyses for high-efficacy DMDs, supplemented by the expert opinions on the usage of these DMDs in clinical practice. Several criteria were discussed by the panel based on different efficacy, safety, and convenience attributes. The panel concluded that all the DMDs available for the treatment of MS have benefits and risks, which should be considered while discussing the treatment plan with the patient. It is important to have a personalized approach based on the risk-benefit assessment for each case. Common considerations while choosing treatments include effectiveness, side effects/safety, and convenience/route of administration. Funding: Merck Serono Middle East FZ LTD.
KW - Disease-modifying drugs
KW - Expert opinion
KW - Gulf region
KW - Multiple sclerosis
KW - Neuroimmunology
UR - http://www.scopus.com/inward/record.url?scp=85071667951&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071667951&partnerID=8YFLogxK
U2 - 10.1007/s40120-019-0129-0
DO - 10.1007/s40120-019-0129-0
M3 - Comment/debate
C2 - 30875021
AN - SCOPUS:85071667951
SN - 2193-8253
VL - 8
SP - 13
EP - 23
JO - Neurology and Therapy
JF - Neurology and Therapy
IS - 1
ER -